Improving therapeutic HPV peptide-based vaccine potency by enhancing CD4+ T help and dendritic cell activation

Journal of Biomedical Science

Volumn 17, Issue 1, 2010, Pages

  Wu, Chao Yi ^a   Monie, Archana ^a   Pang, Xiaowu ^b   Hung, Chien Fu ^a   Wu, T C ^a  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b HOWARD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HPV 16 E7 ALANYLLYSYLPHENYLALANYLVALYLALANYLALANYLTRYPTOPHYLTHREONYLLEUCYLLYSYLALANYLALANYLALANINE; HPV 16 E7 ARGINYLALANYLHISTIDYLTYROSYLASPARAGINYLISOLEUCYLVALYLTHREONYLGLUTAMIC ACID; HPV 16 E7 ARGINYLALANYLHISTIDYLTYROSYLASPARAGINYLISOLEUCYLVALYLTHREONYLGLUTAMYLALANYLLYSYLPHENYLALANYLVALYLALANYLALANYLTRYPTOPHYLTHREONYLLEUCYLLYSYLALANYLALANYLALANINE; POLYINOSINIC POLYCYTIDYLIC ACID; TOLL LIKE RECEPTOR 3; UNCLASSIFIED DRUG; WART VIRUS VACCINE; ANTIVIRUS AGENT; ONCOGENE PROTEIN E7, HUMAN PAPILLOMAVIRUS TYPE 16; PEPTIDE; PROTEIN E7;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN SPECIFICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER THERAPY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL ACTIVATION; CELL SURVIVAL; CELLULAR IMMUNITY; CONTROLLED STUDY; DENDRITIC CELL; DRUG EFFECT; FEMALE; HUMAN PAPILLOMAVIRUS TYPE 16; MOUSE; NONHUMAN; PRIORITY JOURNAL; VACCINATION; ANIMAL; C57BL MOUSE; GENETICS; HUMAN; IMMUNOLOGY; KAPLAN MEIER METHOD; PAPILLOMA VIRUS; UTERINE CERVIX TUMOR; VIROLOGY;

HUMAN PAPILLOMAVIRUS; HUMAN PAPILLOMAVIRUS TYPE 16; MUS;

ANIMALS; ANTIVIRAL AGENTS; CD4-POSITIVE T-LYMPHOCYTES; DENDRITIC CELLS; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MICE; MICE, INBRED C57BL; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS E7 PROTEINS; PAPILLOMAVIRUS VACCINES; PEPTIDES; POLY I-C; UTERINE CERVICAL NEOPLASMS;

EID: 78549282469     PISSN: 10217770     EISSN: 14230127     Source Type: Journal    
DOI: 10.1186/1423-0127-17-88     Document Type: Article

References (27)

1. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. JM Walboomers MV Jacobs MM Manos FX Bosch JA Kummer KV Shah PJ Snijders J Peto CJ Meijer N Munoz, J Pathol 1999 189 12 19 10.1002/(SICI)1096- 9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F 10451482
2. Natural history of human papillomavirus type 16 virus-like particle antibodies in young women. GY Ho YY Studentsov R Bierman RD Burk, Cancer Epidemiol Biomarkers Prev 2004 13 110 116 10.1158/1055-9965.EPI-03-0191 14744741
3. The causal relation between human papillomavirus and cervical cancer. FX Bosch A Lorincz N Munoz CJ Meijer KV Shah, J Clin Pathol 2002 55 244 265 11919208 (Pubitemid 34293391)
4. Persistent human papillomavirus infection and cervical neoplasia. A Ferenczy E Franco, Lancet Oncol 2002 3 11 16 10.1016/S1470-2045(01)00617-9 11905599
5. Papillomaviruses and cancer: from basic studies to clinical application. H zur Hausen, Nat Rev Cancer 2002 2 342 350 10.1038/nrc798 12044010
6. Preventive and therapeutic HPV vaccines. A Monie CF Hung TC Wu, Curr Opin Investig Drugs 2007 8 1038 1050 18058574
7. Opportunities to improve the prevention and treatment of cervical cancer. RB Roden A Monie TC Wu, Curr Mol Med 2007 7 490 503 10.2174/156652407781387127 17691964
8. Human T-cell responses to HLA-A-restricted high binding affinity peptides of human papillomavirus type 18 proteins E6 and E7. MP Rudolf S Man CJ Melief A Sette WM Kast, Clin Cancer Res 2001 7 788s 795s 11300474
9. Natural T-helper immunity against human papillomavirus type 16 (HPV16) E7-derived peptide epitopes in patients with HPV16-positive cervical lesions: identification of 3 human leukocyte antigen class II-restricted epitopes. SH van der Burg ME Ressing KM Kwappenberg A de Jong K Straathof J de Jong A Geluk KE van Meijgaarden KL Franken TH Ottenhoff GJ Fleuren G Kenter CJ Melief R Offringa, Int J Cancer 2001 91 612 618 10.1002/1097-0215(200002)9999:9999<:: AID-IJC1119>3.0.CO;2-C 11267969
10. Continued expression of HPV-16 E7 protein is required for maintenance of the transformed phenotype of cells co-transformed by HPV-16 plus EJ-ras. T Crook JP Morgenstern L Crawford L Banks, Embo J 1989 8 513 519 2542020
11. Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells. MC Feltkamp HL Smits MP Vierboom RP Minnaar JB de JW Drijfhout SJ ter CJ Melief WM Kast, Eur J Immunol 1993 23 2242 2249 10.1002/eji.1830230929 7690326
12. Cooperation between CD4+ and CD8+ T cells: when, where, and how. F Castellino RN Germain, Annu Rev Immunol 2006 24 519 540 10.1146/annurev.immunol. 23.021704.115825 16551258
13. Development of high potency universal DR-restricted helper epitopes by modification of high affinity DR-blocking peptides. J Alexander J Sidney S Southwood J Ruppert C Oseroff A Maewal K Snoke HM Serra RT Kubo A Sette, et al. Immunity 1994 1 751 761 10.1016/S1074-7613(94)80017-0 7895164
14. Immunologic and clinical responses after vaccinations with peptide-pulsed dendritic cells in metastatic renal cancer patients. J Wierecky MR Muller S Wirths E Halder-Oehler D Dorfel SM Schmidt M Hantschel W Brugger S Schroder MS Horger L Kanz P Brossart, Cancer Res 2006 66 5910 5918 10.1158/0008-5472.CAN-05- 3905 16740731
15. Development of experimental carbohydrate-conjugate vaccines composed of Streptococcus pneumoniae capsular polysaccharides and the universal helper T-lymphocyte epitope (PADRE). J Alexander MF del Guercio B Frame A Maewal A Sette MH Nahm MJ Newman, Vaccine 2004 22 2362 2367 10.1016/j.vaccine.2003.11.061 15193395
16. Detection of T helper responses, but not of human papillomavirus-specific cytotoxic T lymphocyte responses, after peptide vaccination of patients with cervical carcinoma. ME Ressing WJ van Driel RM Brandt GG Kenter JH de Jong T Bauknecht GJ Fleuren P Hoogerhout R Offringa A Sette E Celis H Grey BJ Trimbos WM Kast CJ Melief, J Immunother 2000 23 255 266 10.1097/00002371-200003000-00010 10746552
17. Vaccination of metastatic colorectal cancer patients with matured dendritic cells loaded with multiple major histocompatibility complex class I peptides. B Kavanagh A Ko A Venook K Margolin H Zeh M Lotze B Schillinger W Liu Y Lu P Mitsky M Schilling N Bercovici M Loudovaris R Guillermo SM Lee J Bender B Mills L Fong, J Immunother 2007 30 762 772 10.1097/CJI.0b013e318133451c 17893568
18. Antigen presentation and T cell stimulation by dendritic cells. P Guermonprez J Valladeau L Zitvogel C Thery S Amigorena, Annu Rev Immunol 2002 20 621 667 10.1146/annurev.immunol.20.100301.064828 11861614
19. TLR3: interferon induction by double-stranded RNA including poly(I:C). M Matsumoto T Seya, Advanced drug delivery reviews 2008 60 805 812 10.1016/j.addr.2007.11.005 18262679
20. Results of a double-blind placebo-controlled study of the double-stranded RNA drug polyI:polyC12U in the treatment of HIV infection. KA Thompson DR Strayer PD Salvato CE Thompson N Klimas A Molavi AK Hamill Z Zheng D Ventura WA Carter, Eur J Clin Microbiol Infect Dis 1996 15 580 587 10.1007/BF01709367 8874076
21. Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. K-Y Lin FG Guarnieri KF Staveley-O'Carroll HI Levitsky T August DM Pardoll T-C Wu, Cancer Research 1996 56 21 26 8548765
22. DNA Vaccines Encoding Ii-PADRE Generates Potent PADRE-specific CD4(+) T-Cell Immune Responses and Enhances Vaccine Potency. CF Hung YC Tsai L He TC Wu, Mol Ther 2007 15 1211 1219 17356542
23. Maturation of monocyte-derived dendritic cells with Toll-like receptor 3 and 7/8 ligands combined with prostaglandin E2 results in high interleukin-12 production and cell migration. AC Boullart EH Aarntzen P Verdijk JF Jacobs DH Schuurhuis D Benitez-Ribas G Schreibelt MW van de Rakt NM Scharenborg A de Boer M Kramer CG Figdor CJ Punt GJ Adema IJ de Vries, Cancer Immunol Immunother 2008 57 1589 1597 10.1007/s00262-008-0489-2 18322684
24. A clinical grade poly I:C-analogue (Ampligen((R))) promotes optimal DC maturation and Th1-type T cell responses of healthy donors and cancer patients in vitro. H Navabi B Jasani A Reece A Clayton Z Tabi C Donninger M Mason M Adams, Vaccine 2008 18977262
25. Therapeutic vaccination with papillomavirus E6 and E7 long peptides results in the control of both established virus-induced lesions and latently infected sites in a pre-clinical cottontail rabbit papillomavirus model. A Vambutas J DeVoti M Nouri JW Drijfhout GB Lipford VR Bonagura SH van der Burg CJ Melief, Vaccine 2005 23 5271 5280 10.1016/j.vaccine.2005.04.049 16054734
26. Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine. MJ Welters GG Kenter SJ Piersma AP Vloon MJ Lowik DM Berends-van der Meer JW Drijfhout AR Valentijn AR Wafelman J Oostendorp GJ Fleuren R Offringa CJ Melief SH van der Burg, Clin Cancer Res 2008 14 178 187 10.1158/1078-0432.CCR- 07-1880 18172269
27. Phase I immunotherapeutic trial with long peptides spanning the E6 and E7 sequences of high-risk human papillomavirus 16 in end-stage cervical cancer patients shows low toxicity and robust immunogenicity. GG Kenter MJ Welters AR Valentijn MJ Lowik DM Berends-van der Meer AP Vloon JW Drijfhout AR Wafelman J Oostendorp GJ Fleuren R Offringa SH van der Burg CJ Melief, Clin Cancer Res 2008 14 169 177 10.1158/1078-0432.CCR-07-1881 18172268